Vital Signs Podcast: Optiscan

Vital Signs is a podcast series focused on investing, hosted by Senior Health and Biotech journalist Nadine McGrath.

In this episode Nadine chats to CEO + Managing Director at Optiscan (ASX:OIL) Dr Camile Farah, who is also a trained clinician and pathologist.

Optiscan is a global leader in the development, manufacturing, and commercialisation of confocal endomicroscopy-imaging technologies for medical, translational and pre-clinical applications.

Essentially, it’s an approach called optical biopsy, which generates microscopic images in real time, potentially eliminating the need for physical biopsies, which has excited investors and the medical community alike.

Optiscan’s tech could also help alleviate concerns about a growing shortage of pathologists in Australia and internationally delaying medical test results.

In May, Optiscan announced it had signed a know-how agreement with the world-renowned, US-based Mayo Clinic to embark on one of the most significant advances in pathology in nearly 120 years.

To hear Nadine and Camile discuss all this and more, tune in below!

Like to tune in through another app? Just search for Vital Signs with Nadine McGrath and subscribe!

This podcast was developed in collaboration with Optiscan, a Stockhead advertiser at the time of publishing.

The interviews and discussions in this podcast are opinions only and not financial or investment advice. Listeners should obtain independent advice based on their own circumstances before making any financial decisions.